Pneumagen
Clinical-stage biopharmaceutical company developing a glycan-targeted platform and an intranasal multivalent sialic acid–binding therapeutic candidate intended to provide broad, host-directed protection against respiratory viruses. The lead program has completed Phase 1 and a randomized Phase 2 controlled human influenza challenge study with reported reductions in symptomatic influenza and a comparable safety profile to placebo.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Intranasal multivalent sialic acid–binding antiviral (lead candidate)
Investigational self-administered intranasal spray based on engineered multivalent carbohydrate-binding modules designed to bind sialic acid on nasal epithelial cells to block viral attachment and entry; developed as a broad-spectrum, host‑directed prophylactic for respiratory viruses.
HEX17
HEX17 is an investigational intranasal spray based on a multivalent carbohydrate-binding module (mCBM) designed to enhance glycan-binding affinity as a broad-spectrum antiviral prophylactic for respiratory pathogens.
Intranasal multivalent sialic acid–binding antiviral (lead candidate)
Investigational self-administered intranasal spray based on engineered multivalent carbohydrate-binding modules designed to bind sialic acid on nasal epithelial cells to block viral attachment and entry; developed as a broad-spectrum, host‑directed prophylactic for respiratory viruses.
HEX17
HEX17 is an investigational intranasal spray based on a multivalent carbohydrate-binding module (mCBM) designed to enhance glycan-binding affinity as a broad-spectrum antiviral prophylactic for respiratory pathogens.
Services
Engagement with external partners for clinical development, licensing, and strategic collaborations.
Engagement with external partners for clinical development, licensing, and strategic collaborations.
Expertise Areas
- Clinical trial management
- Controlled human infection models (CHIM)
- Protein engineering and multivalent protein design
- Respiratory virus preclinical models
Key Technologies
- Multivalent carbohydrate-binding modules (CBMs)
- Glycan-targeted protein therapeutics
- Intranasal spray delivery
- E. coli recombinant protein expression
News & Updates
Press release announcing company launch and financing to advance a broad-spectrum respiratory antiviral platform.
Peer-reviewed publication describing the Phase II CHIM study evaluating the lead intranasal candidate's efficacy against influenza.
Review or article describing the intranasal biotherapeutic concept and preclinical data supporting broad antiviral activity.
2014 PNAS article on targeting host receptors with engineered proteins to prevent influenza; cited as foundational research origin.
Completed a randomized Phase 2 controlled human influenza challenge study reporting approximately 50% reduction in symptomatic influenza in treated participants versus placebo and comparable safety/tolerability.
Press release announcing company launch and financing to advance a broad-spectrum respiratory antiviral platform.
Peer-reviewed publication describing the Phase II CHIM study evaluating the lead intranasal candidate's efficacy against influenza.
Review or article describing the intranasal biotherapeutic concept and preclinical data supporting broad antiviral activity.
2014 PNAS article on targeting host receptors with engineered proteins to prevent influenza; cited as foundational research origin.
Completed a randomized Phase 2 controlled human influenza challenge study reporting approximately 50% reduction in symptomatic influenza in treated participants versus placebo and comparable safety/tolerability.